Mi­NA Ther­a­peu­tics bags near­ly $30M Se­ries A to push ac­ti­vat­ing mR­NA tech through the clin­ic

Sev­en years af­ter leav­ing in­vest­ment bank­ing to take the helm at Mi­NA Ther­a­peu­tics, CEO Robert Habib is on a mis­sion to de­vel­op a “new class of med­i­cines” us­ing small ac­ti­vat­ing mR­NA tech­nol­o­gy. And on Thurs­day, the Lon­don-based biotech an­nounced it land­ed a mod­est £23 mil­lion (near­ly $30 mil­lion) Se­ries A to work with.

Habib’s fa­ther, the promi­nent Im­pe­r­i­al Col­lege Lon­don pro­fes­sor Nagy Habib, co-found­ed Mi­NA in 2008. The com­pa­ny’s lead mR­NA pro­gram is de­signed to “switch genes on,” and po­ten­tial­ly help treat what the CEO called “the un­drug­gable”: dif­fi­cult-to-treat dis­eases, start­ing with liv­er can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER